ArticleAntimicrobial agents and chemotherapy2018
Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis.Antimicrobial agents and chemotherapy · 2021Pooled it
- A Dose-Finding Study to Guide Use of Verapamil as an Adjunctive Therapy in Tuberculosis.Clinical pharmacology and therapeutics · 2024Trial
- Targeting Membrane Transport and Energy Metabolism for the Identification of Repurposed Drug Candidates AgainstAntibiotics (Basel, Switzerland) · 2026Article
- The Potential Role of Verapamil Against Fluconazole-Induced Torsade de Pointes: A Critical Review.Health science reports · 2026Article
- A two-step screen identifies a small molecule that disrupts membrane voltage and is effective against growing and persister gram-negative bacteria.Microbiology spectrum · 2026Article
- Verapamil Suppresses the Development of Resistance Against Anti-Tuberculosis Drugs in Mycobacteria.International journal of molecular sciences · 2025Article
- Saskemycin, a potent and selective antimycobacterial agent targeting a unique site on the ribosome.Research square · 2025Article
- Beyond Antibiotics: Repurposing Non-Antibiotic Drugs as Novel Antibacterial Agents to Combat Resistance.International journal of molecular sciences · 2025Review
- A potent phenylalkylamine disrupts mycobacterial membrane bioenergetics and augments bactericidal activity of bedaquiline.iScience · 2025Article
- Verapamil and its metabolite norverapamil inhibit theProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Evolution of Small Molecule Inhibitors ofJournal of medicinal chemistry · 2025Article
- Exploration of vanoxerine analogues as antibacterial agents.The Journal of antibiotics · 2025Article
- Article
- The role of metformin in tuberculosis control among TB and diabetes mellitus comorbid individuals.Frontiers in microbiology · 2025Review
- Ajoene: a natural compound with enhanced antimycobacterial and antibiofilm properties mediated by efflux pump modulation and ROS generation against M. Smegmatis.Archives of microbiology · 2024Article
- Discovery of clinical isolation of drug-resistantMicrobiology spectrum · 2024Article
- Proteomic Analysis of Human Macrophages Overexpressing Angiotensin-Converting Enzyme.International journal of molecular sciences · 2024Article
- Shared challenges to the control of complex intracellular neglected pathogens.Frontiers in public health · 2024Review
- In vitro and in vivo evaluation of dual Clofazimine and Verapamil loaded PLGA nanoparticles.Indian journal of clinical biochemistry : IJCB · 2023Article
- Mycobacterium tuberculosis Gene Expression Associated With Fluoroquinolone Resistance and Efflux Pump Inhibition.The Journal of infectious diseases · 2023Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.